Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX2 | Q96LB1 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.64 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.64 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.64 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.64 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.64 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.64 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.63 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.58 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Norcodeine SCHEMBL120271 | 1.00 | MRGPRX2 (1.00) | MRGPRX2MAPTOPRM1OPRK1OPRD1 | |
| Norcodeine SCHEMBL29776979 | 1.00 | MRGPRX2 (1.00) | MRGPRX2MAPTOPRM1OPRK1OPRD1 | |
| Norcodeine SCHEMBL18462800 | 1.00 | MRGPRX2 (1.00) | MRGPRX2MAPTOPRM1OPRK1OPRD1 | |
| Norcodeine SCHEMBL16922132 | 1.00 | MRGPRX2 (1.00) | MRGPRX2MAPTOPRM1OPRK1OPRD1 | |
| Norcodeine SCHEMBL12638889 | 1.00 | MRGPRX2 (1.00) | MRGPRX2MAPTOPRM1OPRK1OPRD1 | |
| Norcodeine SCHEMBL24541888 | 1.00 | MRGPRX2 (1.00) | MRGPRX2MAPTOPRM1OPRK1OPRD1 | |
| Norcodeine SCHEMBL4856570 | 0.99 | MRGPRX2 (0.98) | MRGPRX2MAPTOPRM1OPRK1OPRD1 | |
| Norcodeine SCHEMBL6220787 | 0.99 | MRGPRX2 (0.98) | MRGPRX2MAPTOPRM1OPRK1OPRD1 | |
| Norcodeine SCHEMBL7593070 | 0.98 | MRGPRX2 (0.96) | MRGPRX2MAPTOPRM1OPRK1OPRD1 | |
| Codeine SCHEMBL20703798 | 0.90 | OPRM1 (0.83) | MRGPRX2MAPTOPRM1OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1008 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118871420-A | Process for the preparation of codeine, its derivatives and intermediates | 暨南大学 | 2024-10-29 | — | — | CN | claimed |
| US-20240209403-A1 | METHODS OF PRODUCING MORPHINAN ALKALOIDS AND DERIVATIVES | HERCULES CAPITAL, INC., AS AGENT | 2024-06-27 | — | — | US | claimed |
| US-20240165022-A1 | Pharmaceutical Formulation | KLARIA PHARMA HOLDING AB (SE) | 2024-05-23 | — | — | US | claimed |
| US-11904049-B2 | Pharmaceutical formulation | KLARIA PHARMA HOLDING AB (SE) | 2024-02-20 | — | — | US | claimed |
| WO-2023164889-A1 | METHOD FOR PREPARING CODEINE AND DERIVATIVE AND INTERMEDIATE THEREOF | 暨南大学 | 2023-09-07 | — | — | WO | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| CN-116670170-A | Use of LEPR agonists for pain | 瑞泽恩制药公司 | 2023-08-29 | — | — | CN | claimed |
| EP-4214232-A2 | USE OF LEPR AGONISTS FOR PAIN | Regeneron Pharmaceuticals, Inc. (US) | 2023-07-26 | — | — | EP | claimed |
| CN-116217641-A | Synthesis method of morphine-D3-6-beta-D-glucuronide and intermediate compound thereof | 上海原思标物科技有限公司 | 2023-06-06 | — | — | CN | claimed |
| EP-2633305-B1 | AUTOMATED SYSTEM FOR SAMPLE PREPARATION AND ANALYSIS | THERMO FISHER SCIENTIFIC OY (FI) | 2023-03-01 | — | — | EP | claimed |
| WO-1999002529-A1 | PREPARATION OF OXYMORPHONE, OXYCODONE AND DERIVATIVES | PENICK CORPORATION (US) | 1999-01-21 | — | — | WO | claimed |
| CN-1196955-A | Thebaica giving-up vaccinum for man | KUNMING BIOLOG TECH ENGINEERIN (CN) | 1998-10-28 | — | — | CN | claimed |
| JP-2694156-B2 | — | US HEALTH (US) | 1997-12-24 | — | — | JP | claimed |
| EP-0496830-A4 | TOTAL SYNTHESIS OF NORTHEBAINE, NORMORPHINE, NOROXYMORPHONE ENANTIOMERS AND DERIVATIVES VIA N-NOR INTERMEDIATES | US HEALTH (US) | 1992-09-30 | — | — | EP | claimed |
| EP-0496830-A1 | TOTAL SYNTHESIS OF NORTHEBAINE, NORMORPHINE, NOROXYMORPHONE ENANTIOMERS AND DERIVATIVES VIA N-NOR INTERMEDIATES | THE UNITED STATES OF AMERICA as represented by the Secretary UNITED STATES DEPARTMENT OF COMMERCE (US) | 1992-08-05 | — | — | EP | claimed |
| EP-0261148-B1 | ORALLY ACTIVE NONADDICTING ANALGESICS | SRI INTERNATIONAL (US) | 1992-01-02 | — | — | EP | claimed |
| WO-1991005768-A1 | TOTAL SYNTHESIS OF NORTHEBAINE, NORMORPHINE, NOROXYMORPHONE ENANTIOMERS AND DERIVATIVES VIA N-NOR INTERMEDIATES | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, UNITED STATES DEPARTMENT OF COMMERCE (US) | 1991-05-02 | — | — | WO | claimed |
| US-4940586-A | Skin permeation enhancer compositions using sucrose esters | ALZA CORPORATION (US) | 1990-07-10 | — | — | US | claimed |
| EP-0261148-A1 | ORALLY ACTIVE NONADDICTING ANALGESICS. | STANFORD RES INST INT (US) | 1988-03-30 | — | — | EP | claimed |
| WO-1987005903-A2 | ORALLY ACTIVE NONADDICTING ANALGESICS | SRI INTERNATIONAL (US) | 1987-10-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11904049-B2 | Pharmaceutical formulation | OGFR, OPRL1, OPRM1 | MRGPRX2 15/4885MAPT 1459/4885OPRM1 3/4885 |
| US-20240165022-A1 | Pharmaceutical Formulation | OGFR, OPRL1, OPRM1 | MRGPRX2 15/4885MAPT 1459/4885OPRM1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.